Analyst: Bavarian Nordic RSV partnership could be first of many

Bavarian Nordic’s partnership with Nuance Pharma, which was announced on Monday, is important and very positive for the Danish firm, says Analyst Søren Lønfoft Hansen, mentioning that this might be the first of many.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

On Monday, Bavarian Nordic signed a very important and positive deal with Nuance Pharma, says Senior Equity Analyst at Sydbank Søren Løntoft Hansen. He has kept an eye on Bavarian’s stock following the news, reporting that the Danish company has had a markedly better start than the general market today.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs